Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $115 | $48 | $45 | $43 |
| % Growth | 142.4% | 5.1% | 5.9% | – |
| Cost of Goods Sold | $25 | $3 | $5 | $3 |
| Gross Profit | $91 | $45 | $40 | $40 |
| % Margin | 78.5% | 93.9% | 89.3% | 93.4% |
| R&D Expenses | $21 | $7 | $50 | $4 |
| G&A Expenses | $28 | $20 | $19 | $26 |
| SG&A Expenses | $28 | $20 | $19 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$14 | $10 | $8 | $20 |
| Operating Expenses | $36 | $36 | $77 | $50 |
| Operating Income | $55 | $8 | -$36 | -$10 |
| % Margin | 47.6% | 17.7% | -79.9% | -22.5% |
| Other Income/Exp. Net | $86 | $3 | -$14 | -$30 |
| Pre-Tax Income | $141 | $11 | -$50 | -$39 |
| Tax Expense | $24 | $6 | -$8 | -$8 |
| Net Income | $117 | $5 | -$42 | -$31 |
| % Margin | 101.6% | 10.2% | -93.6% | -72.6% |
| EPS | 5.99 | 0.25 | -2.21 | -1.64 |
| % Growth | 2,296% | 111.3% | -34.8% | – |
| EPS Diluted | 5.68 | 0.24 | -2.21 | -1.64 |
| Weighted Avg Shares Out | 19 | 19 | 19 | 19 |
| Weighted Avg Shares Out Dil | 20 | 20 | 19 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $2 | $2 |
| Interest Expense | $0 | $1 | $1 | $1 |
| Depreciation & Amortization | $8 | $9 | $9 | $9 |
| EBITDA | $149 | $21 | -$41 | -$30 |
| % Margin | 129.2% | 43.9% | -89.4% | -69.3% |